AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24167368
PubMed Central
PMC3776368
DOI
10.1155/2013/761537
Knihovny.cz E-resources
- MeSH
- Drug Resistance, Neoplasm genetics MeSH
- Antineoplastic Agents, Hormonal therapeutic use MeSH
- Carcinoma diagnosis drug therapy genetics metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger genetics metabolism MeSH
- Mucoproteins MeSH
- Biomarkers, Tumor genetics metabolism MeSH
- Breast Neoplasms diagnosis drug therapy genetics metabolism MeSH
- Oncogene Proteins MeSH
- Postmenopause metabolism MeSH
- Proteins genetics metabolism MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Tamoxifen therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- AGR2 protein, human MeSH Browser
- Antineoplastic Agents, Hormonal MeSH
- RNA, Messenger MeSH
- Mucoproteins MeSH
- Biomarkers, Tumor MeSH
- Oncogene Proteins MeSH
- Proteins MeSH
- Tamoxifen MeSH
Endocrine resistance is a significant problem in breast cancer treatment. Thus identification and validation of novel resistance determinants is important to improve treatment efficacy and patient outcome. In our work, AGR2 expression was determined by qRT-PCR in Tru-Cut needle biopsies from tamoxifen-treated postmenopausal breast cancer patients. Our results showed inversed association of AGR2 mRNA levels with primary treatment response (P = 0.0011) and progression-free survival (P = 0.0366) in 61 ER-positive breast carcinomas. As shown by our experimental and clinical evaluations, elevated AGR2 expression predicts decreased efficacy of tamoxifen treatment. From this perspective, AGR2 is a potential predictive biomarker enabling selection of an optimal algorithm for adjuvant hormonal therapy in postmenopausal ER-positive breast cancer patients.
See more in PubMed
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Ca: A Cancer Journal for Clinicians. 2005;55(2):74–108. PubMed
Katzenellenbogen BS, Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Seminars in Oncology. 2004;31(1):28–38. PubMed
Robertson JFR, Cannon PM, Nicholson RI, Blamey RW. Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer. International Journal of Biological Markers. 1996;11(1):29–35. PubMed
Hrstka R, Nenutil R, Fourtouna A, et al. The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene. 2010;29(34):4838–4847. PubMed
Innes HE, Liu D, Barraclough R, et al. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. British Journal of Cancer. 2006;94(7):1057–1065. PubMed PMC
Thompson DA, Weigel RJ. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochemical and Biophysical Research Communications. 1998;251(1):111–116. PubMed
Pohler E, Craig AL, Cotton J, et al. The Barrett’s antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Molecular and Cellular Proteomics. 2004;3(6):534–547. PubMed
Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Research. 2005;65(9):3796–3805. PubMed
Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Research. 2008;68(2):492–497. PubMed
Hengel SM, Murray E, Langdon S, et al. Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. Journal of Proteome Research. 2011;10(10):4567–4578. PubMed PMC
Abd El-Rehim DM, Ball G, Finder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. International Journal of Cancer. 2005;116(3):340–350. PubMed
McCarty KS, Jr., Miller LS, Cox EB, Konrath J, McCarty KS., Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archives of Pathology and Laboratory Medicine. 1985;109(8):716–721. PubMed
Hodges LC, Cook JD, Lobenhofer EK, et al. Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Molecular Cancer Research. 2003;1(4):300–311. PubMed
Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clinical Cancer Research. 2004;10(17):5670–5676. PubMed
Dong A, Gupta A, Pai RK, Tun M, Lowe AW. The human adenocarcinoma-associated gene, AGR2, induces expression of Amphiregulin through hippo pathway co-activator YAP1 activation. The Journal of Biological Chemistry. 2011;286(20):18301–18310. PubMed PMC
Hrstka R, Murray E, Brychtova V, Fabian P, Hupp TR, Vojtesek B. Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Letters. 2013;333:187–193. PubMed
AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway